Host: Anna Lea Doyle, principal, Deloitte Consulting LLP
For many organizations, the recent pandemic has shone light on capital, as either the lifeblood of business or under-performing assets that might not be fit for purpose in the next normal. Crises can serve as a reflection point for organizations to fundamentally challenge their strategic goals and portfolios. Organizations experiencing significant disruption resulting from the global pandemic are likely considering many options for raising capital to fund operations or future investment while reviewing their portfolios to consider strategic divestment of non-core assets to strengthen the remaining organization. We’ll discuss:
- The current state of the M&A transaction market and how organizations are recovering.
- Lessons learned from previous downturns to help position dealmakers to execute on marketplace opportunities.
- Sell-side response strategies to build resilient portfolios and thrive in the “next normal”.
Meet the speakers
Anna Lea Doyle
Anna is the Global Consulting Mergers & Acquisitions Leader, and has over 10 years of global, cross broader M&A sales and delivery. Over 20 years she has integration and divestiture engagements ranging from $450M to $135B serving many Global Crown Jewel clients. Additionally, for the US M&A Offering, Anna leads the M&A / Restructuring Management Office Market Offering, as well as the Global Divestiture Leader.
Ryan J. Stecz
Ryan is a partner with Deloitte Tax LLP in the M&A Transaction Services practice, based in Chicago. Ryan has more than 20 years of public accounting experience including more than 15 years as a dedicated M&A specialist. He has experience in advising financial and strategic buyers on due diligence and deal structuring in a range of industries including consumer and industrial products, healthcare, and technology. Further, Ryan has significant experience advising clients on sell side transactions including the preparation of carve-out financial statements, vendor due diligence reports, tax structuring and modeling exercises, and the tax implications associated with selling S corporations. Ryan’s experience in advising financial and strategic buyers on due diligence and deal structuring in a range of industries has provided him with deep insights into the sell-side process as well as the needs and motivations of acquiring entities. He has been a leading contributor to several articles covering tax aspects of preparing carve-out financial statements and selling S corporations. Ryan has spoken on a variety of M&A sell side related topics including vendor due diligence best practices, tax considerations of carve-out financial statements and selling Subchapter S corporations. He has also been a guest-lecturer at the University of Notre Dame’s Masters in Taxation program. He currently serves as a member of the St. Benedict Preparatory school’s endowment board.
Chris is a partner and the leader of Deloitte’s US Life Sciences M&A practice in addition to the Global Life Sciences & Healthcare Financial Advisory leader. Chris has more than 20 years of experience with Deloitte and has experience in advising financial and strategic buyers and sellers on many aspects of acquisitions and divestitures including: due diligence, accounting structuring, financial reporting, and pro forma financial statements. He has led domestic and global M&A teams on transactions of varying sizes. Chris has significant experience in life sciences and has worked on transactions in the areas of pharmaceuticals, pharmaceutical distribution, orthopedics, medical and surgical products, spine products, diagnostics and lab services. In addition, Chris presents at various industry and technical seminars sponsored by Deloitte and external organizations, and has contributed to Deloitte-sponsored health care publications.